{
    "clinical_study": {
        "@rank": "30278", 
        "arm_group": [
            {
                "arm_group_label": "HC-ER + 40% Alcohol", 
                "arm_group_type": "Experimental", 
                "description": "Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol."
            }, 
            {
                "arm_group_label": "HC-ER + 20% Alcohol", 
                "arm_group_type": "Experimental", 
                "description": "Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol."
            }, 
            {
                "arm_group_label": "HC-ER + 0% Alcohol", 
                "arm_group_type": "Experimental", 
                "description": "Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the influence of co-ingestion of alcohol on HC-ER."
        }, 
        "brief_title": "A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)", 
        "completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Determine the influence of co-ingestion of alcohol on the safety, pharmacokinetics, and\n      relative bioavailability of HC-ER 50 mg under fasted conditions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, ages 21 to 45.\n\n          -  Female, must be of non-childbearing potential.\n\n          -  Non-smokers for at least 3 months or light smokers (less than 10 pack-years).\n\n          -  History of moderate consumption of between 7-21 units of alcohol per week.\n\n          -  Weighed at least 65 kg with a BMI \u226519 and \u226435 kg/m2.\n\n          -  Were medically healthy with no clinically significant abnormalities.\n\n          -  Voluntarily consented to participate in the study.\n\n          -  Were prepared to be compliant with the study procedures.\n\n        Exclusion Criteria:\n\n          -  Women who were pregnant or breastfeeding.\n\n          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or\n             psychiatric disease.\n\n          -  History or presence of alcoholism or drug abuse.\n\n          -  Hypersensitivity or idiosyncratic reaction to morphine, hydrocodone (Vicodin) or\n             other opioids; naltrexone, naloxone, or other opioid antagonist.\n\n          -  History of no alcohol intake (alcohol-naive) or less than moderate alcohol intake.\n\n          -  History of alcohol intake exceeding the equivalence of 21 units/week or exceeding the\n             average of 3 drinks per day.\n\n          -  Surgery of the gastrointestinal tract which would interfere with absorption of the\n             study drug.\n\n          -  Taken hepatic enzyme inducing drugs (e.g., Nizoral, Tagamet) within the previous 3\n             months.\n\n          -  Taken prescription medications within the previous 14 days or over the counter (OTC)\n             medications within the previous 7 days prior to Day 1 Period 1.\n\n          -  Sitting blood pressure was less than 110/45 mmHg at screening.\n\n          -  On a special diet (except for vegetarians who agree to abide by study diet) during\n             the 28 days prior to the first dose and throughout the study.\n\n          -  Significant blood donation or loss within 56 days prior to first dose of HC-ER.\n\n          -  Plasma donation within 7 days prior to first dose of HC-ER.\n\n          -  Hemoglobin value less than 12.0 g/dL.\n\n          -  Participated in another clinical trial within 28 days prior to first dose of HC-ER.\n\n          -  Positive urine test for drugs of abuse.\n\n          -  Positive test for, or had been treated for hepatitis B, hepatitis C or HIV."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126917", 
            "org_study_id": "ZX002-0901"
        }, 
        "intervention": [
            {
                "arm_group_label": "HC-ER + 40% Alcohol", 
                "description": "HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state", 
                "intervention_name": "HC-ER + 40% Alcohol", 
                "intervention_type": "Drug", 
                "other_name": "Zohydro ER"
            }, 
            {
                "arm_group_label": "HC-ER + 20% Alcohol", 
                "description": "HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state", 
                "intervention_name": "HC-ER + 20% Alcohol", 
                "intervention_type": "Drug", 
                "other_name": "Zohydro ER"
            }, 
            {
                "arm_group_label": "HC-ER + 0% Alcohol", 
                "description": "HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state", 
                "intervention_name": "HC-ER + 0% Alcohol", 
                "intervention_type": "Drug", 
                "other_name": "Zohydro ER"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethanol", 
                "Hydrocodone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Phase 1", 
            "Alcohol", 
            "Hydrocodone Bitartrate", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "number_of_arms": "3", 
        "official_title": "Single-center, Open-Label, 3-Period Crossover, Phase 1 Study to Evaluate the Pharmacokinetics of Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules 50 mg When Co-Administered With Alcohol in Healthy Subjects Under Fasted Conditions", 
        "overall_official": {
            "affiliation": "Zogenix, Inc.", 
            "last_name": "James Kissling, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assess the rate and extent of absorption of HC-ER 50 mg capsule following co-ingestion of alcohol under fasted conditions.", 
            "safety_issue": "No", 
            "time_frame": "Day 1 through Day 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Zogenix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zogenix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}